<unk>  (INN, used as the fumarate under the brand name Toviaz) is an antimuscarinic drug developed by Schwarz Pharma AG to treat overactive bladder syndrome (OAB). It was approved by the European Medicines Agency in April 2007, the US Food and Drug Administration on October 31, 2008 and Health Canada on February 9, 2012.<unk>  is a prodrug. It is broken down into its active metabolite, desfesoterodine, by plasma esterases.
Fesoterodine
Tolterodine
Ingenol mebutate
Ethinylestradiol sulfonate
Hydrastinine
Bisoctrizole
Ibotenic acid
Lapisteride